These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34009531)

  • 41. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia.
    Kane JM; Detke HC; Naber D; Sethuraman G; Lin DY; Bergstrom RF; McDonnell D
    Am J Psychiatry; 2010 Feb; 167(2):181-9. PubMed ID: 20008947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Jan; 63(1):140-50. PubMed ID: 18834452
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug safety evaluation of olanzapine pamoate.
    Schöttle D; Kuhnigk O; Naber D
    Expert Opin Drug Saf; 2013 Nov; 12(6):897-903. PubMed ID: 24024627
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of 5HT1A and 5HT2A receptors and default mode network in olanzapine-induced somnambulism.
    Das S; Gupta R; Dhyani M; Sah D; Maity J
    Neurol India; 2017; 65(2):373-374. PubMed ID: 28290400
    [No Abstract]   [Full Text] [Related]  

  • 45. Olanzapine and delirium: lesson from clinical practice.
    Singh D; Forlano R
    Aust N Z J Psychiatry; 2008 May; 42(5):433-4. PubMed ID: 18499932
    [No Abstract]   [Full Text] [Related]  

  • 46. Are dexmedetomidine and olanzapine suitable to control delirium in critically ill elderly patients? A retrospective cohort study.
    Liu S; Zhao R; Yang R; Zhao H; Ji C; Duan M; Liu J
    Biomed Pharmacother; 2021 Jul; 139():111617. PubMed ID: 33915500
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Postinjection Delirium Syndrome Associated With Olanzapine Long-Acting Injectable.
    Bengtsson C; Nilsson BM; Bodén R
    J Clin Psychopharmacol; 2016 Aug; 36(4):388-9. PubMed ID: 27159773
    [No Abstract]   [Full Text] [Related]  

  • 48. Switch-associated adverse events: focus on olanzapine.
    Xu L; Krishnaswamy S
    Australas Psychiatry; 2018 Dec; 26(6):635-639. PubMed ID: 30407073
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.
    Samalin L; Garay R; Ameg A; Llorca PM
    Expert Opin Drug Saf; 2016; 15(3):403-11. PubMed ID: 26761429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-acting injectable olanzapine: post-injection syndrome.
    Prescrire Int; 2017 Feb; 26(179):46. PubMed ID: 30726633
    [No Abstract]   [Full Text] [Related]  

  • 51. Olanzapine/Samidorphan: First Approval.
    Paik J
    Drugs; 2021 Aug; 81(12):1431-1436. PubMed ID: 34304374
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fever, delirium, autonomic instability, and monocytosis associated with olanzapine.
    Robinson RL; Burk MS; Raman S
    J Postgrad Med; 2003; 49(1):96. PubMed ID: 12865583
    [No Abstract]   [Full Text] [Related]  

  • 53. High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey.
    Ono S; Sugai T; Suzuki Y; Yamazaki M; Shimoda K; Mori T; Ozeki Y; Matsuda H; Sugawara N; Yasui-Furukori N; Okamoto K; Sagae T; Someya T
    BMC Psychiatry; 2018 Jun; 18(1):180. PubMed ID: 29879941
    [TBL] [Abstract][Full Text] [Related]  

  • 54. One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia.
    Fefeu M; De Maricourt P; Cachia A; Hoertel N; Vacheron MN; Wehbe E; Rieu C; Olie JP; Krebs MO; Gaillard R; Plaze M
    Psychiatry Res; 2018 Dec; 270():205-210. PubMed ID: 30267984
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Valproate and high dosage of zotepine induced acute delirium: a case report.
    Hsu WY; Kuo SY; Huang SS; Chang TG; Chiu NY
    Br J Clin Pharmacol; 2012 Mar; 73(3):486-8. PubMed ID: 21988532
    [No Abstract]   [Full Text] [Related]  

  • 56. [Post-injection syndrome after depot injection of olanzapine].
    Wilms EB; van der Velden MT; van Essen FH; ten Brink C
    Ned Tijdschr Geneeskd; 2014; 159():A7885. PubMed ID: 25589277
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A review of olanzapine pamoate.
    Chue P; Chue J
    Expert Opin Pharmacother; 2012 Aug; 13(11):1661-70. PubMed ID: 22746160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intramuscular olanzapine vs. intramuscular short-acting antipsychotics: safety, tolerability and the switch to oral antipsychotic medication in patients with schizophrenia or acute mania.
    Chandrasena R; Dvoráková D; Lee SI; Loza N; Mosolov SN; Osváth P; Pregelj P; Walton RJ; Karagianis J; Treuer T
    Int J Clin Pract; 2009 Aug; 63(8):1249-58. PubMed ID: 19558486
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early prediction of olanzapine-induced weight gain for schizophrenia patients.
    Lin CH; Lin SC; Huang YH; Wang FC; Huang CJ
    Psychiatry Res; 2018 May; 263():207-211. PubMed ID: 29574355
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.
    Correll CU; Newcomer JW; Silverman B; DiPetrillo L; Graham C; Jiang Y; Du Y; Simmons A; Hopkinson C; McDonnell D; Kahn RS
    Am J Psychiatry; 2020 Dec; 177(12):1168-1178. PubMed ID: 32791894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.